Heyu-B (02256) issued an announcement. The company's subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu...
Zhitong Finance App News, Heyu-B (02256) announced that Shanghai Heyu Biomedical Technology Co., Ltd. (Fuyu Pharmaceutical), a subsidiary of the company, announced that its self-developed high-selective small molecule FGFR4 inhibitor ipagotinib (ABSK011) has been certified as an orphan drug by the US Food and Drug Administration (FDA) to treat hepatocellular carcinoma (Hepatocellular carcinoma, HCC).